InsidersTradesSigma
Track the Biomea Fusion, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Biomea Fusion, Inc. has published 34 public disclosures. Market capitalisation: €92.5m. The latest transaction was disclosed on 15 December 2025 (Acquisition). Among the most active insiders: A2A Pharmaceuticals, Inc.. All data is accessible without an account.
34
Insider Decl.
n/a
Thresholds
€18m
16 ops.
Buy Volume
€24m
8 ops.
Sell Volume
54Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 December 2025
Declarations34 total
30,000 shares@ US$1.43331.3% of flowCommon StockSEC:0001193125-25-319222:0
Canonical exit: 11 Mar 2026 (T+90)
100,000 shares@ US$0.991839.9% of flowCommon StockSEC:0001193125-25-308091:0
Canonical exit: 2 Mar 2026 (T+90)
40,000 shares@ US$1.10131.3% of flowCommon StockSEC:0001193125-25-305287:0
Canonical exit: 26 Feb 2026 (T+90)
40,000 shares0Common StockSEC:0000950170-25-108041:0
495 shares@ US$6.1541.2% of flowCommon StockSEC:0000950170-24-132253:0
10,000 shares@ US$10.0670.2% of flowCommon StockSEC:0000950170-24-110858:0
Canonical exit: 29 Dec 2024 (T+90)
349 shares@ US$8.942100.0% of flowCommon StockSEC:0000950170-24-072493:0
4,448 shares@ US$3.78256.4% of flowCommon StockSEC:0000950170-24-072494:0
3,000 shares0Common StockSEC:0000950170-24-000956:0
1,345 shares@ US$3.78251.9% of flowCommon StockSEC:0000950170-23-067424:0
4,273 shares@ US$3.78256.2% of flowCommon StockSEC:0000950170-23-026142:0
75,000 shares@ US$33.819.5% of flowCommon StockSEC:0001859061-23-000007:0
25,000 shares@ US$33.843.1% of flowCommon StockSEC:0001859061-23-000006:0
100,000 shares@ US$33.993112.4% of flowCommon StockSEC:0001859061-23-000005:0
200,000 shares@ US$29.118821.4% of flowCommon StockSEC:0001859061-23-000004:0
200,000 shares@ US$31.2523.1% of flowCommon StockSEC:0001859061-23-000002:0
200,000 shares@ US$31.2523.1% of flowCommon StockSEC:0001859061-23-000003:0
400,000 shares@ US$30.00100.0% of flowCommon StockSEC:0000929638-23-001057:0
Canonical exit: 28 Jun 2023 (T+90)
2,400 shares@ US$17.000.6% of flowCommon StockSEC:0000899243-23-004569:0
Canonical exit: 14 Jul 2021 (T+90)
2,518 shares@ US$3.78253.8% of flowCommon StockSEC:0000899243-22-037438:0
5,000 shares@ US$7.9329.8% of flowCommon StockSEC:0000899243-22-036010:0
Canonical exit: 12 Feb 2023 (T+90)
4,100 shares@ US$7.630712.6% of flowCommon StockSEC:0000899243-22-035697:0
Canonical exit: 9 Feb 2023 (T+90)
30,684 shares@ US$13.8721.7% of flowCommon StockSEC:0001859061-22-000002:0
Canonical exit: 14 Nov 2022 (T+90)
34,658 shares@ US$11.211.5% of flowCommon StockSEC:0001859061-22-000001:0
34,658 shares@ US$11.760.40% mcap37.5% of flowCommon StockSEC:0001856641-22-000001:0
25 of 34 declarations
关于 Biomea Fusion, Inc.
Biomea Fusion, Inc. 是一家美国生物制药公司，在美国纳斯达克市场上市，股票代码为 BMEA。该公司专注于代谢健康，战略重点是糖尿病和肥胖症。它于 2017 年 8 月作为特拉华州实体成立，此后将其企业形象从更广泛的生物技术公司转变为一家更专注于临床阶段代谢药物的公司。Biomea 总部位于加利福尼亚州圣卡洛斯，位于旧金山湾区生物技术走廊。([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai)) Biomea 目前的业务围绕两个主要的口服临床项目：icovamenib 和 BMF-650。该公司将 Icovamenib 描述为一种潜在的同类首创共价 menin 抑制剂，正在开发用于治疗糖尿病，包括对标准治疗（如基于 GLP-1 的治疗）控制不佳的 2 型糖尿病患者。BMF-650 是一种下一代口服 GLP-1 受体激动剂候选药物，设计用于肥胖症和更广泛的代谢疾病应用。该公司对口服疗法的重视具有战略重要性，因为它旨在解决一个主要的市场需求：将显著的代谢功效与比目前主导该类别的大多数注射疗法更方便的给药途径相结合。([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai)) 从竞争角度来看，Biomea 仍然是一家临床阶段、尚未盈利的生物技术公司，这意味着投资案例高度依赖于临床结果、耐受性、监管进展和资金执行。尽管如此，该公司的定位是差异化的。Biomea 不仅仅作为另一个糖尿病或肥胖症的进入者进行竞争，它还试图服务于当前标准治疗未能满足的患者亚群，同时通过 BMF-650 将其代谢平台扩展到肥胖症。这使得该公司能够接触到两个庞大且竞争激烈的治疗市场，但其叙述围绕口服便利性和如果数据继续验证该机制则可能具有疾病修饰作用。([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and/?utm_source=openai)) 最近的发展主要集中在临床执行上。2026 年，Biomea 宣布其新启动的 icovamenib 2 型糖尿病 II 期项目 COVALENT-211 和 COVALENT-212 的首位患者给药。该公司还表示正在推进 BMF-650，预计在 2026 年上半年从一项 I 期肥胖症研究中获得 28 天的体重减轻数据。与此同时，Biomea 继续在科学会议上展示数据和公司更新，并强调其资本结构旨在为 2027 年的关键临床里程碑提供资金。因此，对于讲法语的投资者而言，BMEA 最好被视为美国纳斯达克市场的一家高风险、高回报的生物技术公司，其价值创造取决于下一组临床数据以及公司将有前景的生物学转化为可注册资产的能力。([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-announces-first-patient-dosed-newly-initiated?utm_source=openai))
